China Medical System (CHSYF) Holdings announced that on 28 July, the New Drug Application for improved new drug ZUNVEYL has been accepted by the National Medical Products Administration of China. The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHSYF:
- China Medical System’s Alzheimer’s Drug ZUNVYL Gains Approval in China
- China Medical System Holdings Secures Secondary Listing on Singapore Exchange
- China Medical System’s CMS-D001 Receives Approval for Atopic Dermatitis Trials
- China Medical System Holdings Plans Secondary Listing on Singapore Exchange
- China Medical System Holdings Announces Eligibility for Secondary Listing on Singapore Exchange